Cellino Overview
- Year Founded
-
2017

- Status
-
Private
- Employees
-
136

- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$25M
- Investors
-
13
Cellino General Information
Description
Developer of an AI-guided laser editing platform designed to make personalized, autologous cell therapies accessible to patients. The company's platform facilitates an automated process to generate autologous induced pluripotent stem cells at scale using image-guided machine learning, single-cell laser processing, and robotics, enabling healthcare providers to accelerate the development of life-saving medicines for patients.
Contact Information
Website
www.cellinobio.comCorporate Office
- 750 Main Street
- Cambridge, MA 02139
- United States
Corporate Office
- 750 Main Street
- Cambridge, MA 02139
- United States
Cellino Timeline
Cellino Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
9. Grant | 11-Sep-2024 | $25M | Completed | Generating Revenue | ||
8. Later Stage VC (Series A) | 25-Jan-2022 | Completed | Generating Revenue | |||
7. Seed Round | 01-Feb-2021 | Completed | Generating Revenue | |||
6. Seed Round | 09-Aug-2019 | Completed | Generating Revenue | |||
5. Accelerator/Incubator | 03-May-2019 | Completed | Generating Revenue | |||
4. Accelerator/Incubator | 06-Nov-2017 | Completed | Generating Revenue | |||
3. Grant | 09-Feb-2017 | Completed | Generating Revenue | |||
2. Accelerator/Incubator | Completed | Generating Revenue | ||||
1. University Spin-Out | 01-Jan-2017 | Completed | Generating Revenue |
Cellino Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | ||||||||
Seed-2 | ||||||||
Seed | 328,948 | $0.000100 | $4.56 | $4.56 | 1x | $4.56 | 3.83% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cellino Patents
Cellino Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240067917-A1 | Systems and methods for cell manufacturing | Pending | 15-Aug-2022 | ||
US-20240067914-A1 | Systems and methods for cell manufacturing | Pending | 15-Aug-2022 | ||
US-20240067916-A1 | Systems and methods for cell manufacturing | Pending | 15-Aug-2022 | ||
US-20240052321-A1 | Systems and methods for cell manufacturing | Pending | 15-Aug-2022 | ||
AU-2023324685-A1 | Systems and methods for cell manufacturing | Pending | 15-Aug-2022 | C12N5/0696 |
Cellino Signals
Cellino Investors (13)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
ARPA-H | Government | |||
Felicis | Venture Capital | Minority | ||
Hawktail | Venture Capital | Minority | ||
Leaps by Bayer | Corporate Venture Capital | Minority | ||
8VC | Venture Capital | Minority |
Cellino FAQs
-
When was Cellino founded?
Cellino was founded in 2017.
-
Where is Cellino headquartered?
Cellino is headquartered in Cambridge, MA.
-
What is the size of Cellino?
Cellino has 136 total employees.
-
What industry is Cellino in?
Cellino’s primary industry is Other Healthcare Technology Systems.
-
Is Cellino a private or public company?
Cellino is a Private company.
-
What is Cellino’s current revenue?
The current revenue for Cellino is
. -
How much funding has Cellino raised over time?
Cellino has raised $100M.
-
Who are Cellino’s investors?
ARPA-H, Felicis, Hawktail, Leaps by Bayer, and 8VC are 5 of 13 investors who have invested in Cellino.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »